Trial Profile
A real world study for the efficacy and safety of apatinib mesylate in treament of gastric cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 02 Nov 2018 New trial record